FDA in Brief: FDA reminds patients, health care professionals and laboratory personnel about the potential for biotin interference with certain test results, especially specific tests to aid in heart attack diagnoses

https://www.fda.gov/news-events/fda-brief/fda-brief-fda-reminds-patients-health-care-professionals-and-laboratory-personnel-about-potential?utm_campaign=110519_FIB_FDA%20reminds%20public%20of%20possible%20biotin%20interference%20for%20certain%20tests&utm_medium=email&utm_source=Eloqua

FDA in Brief: FDA reminds patients, health care professionals and laboratory personnel about the potential for biotin interference with certain test results, especially specific tests to aid in heart attack diagnoses 

Today, the U.S. Food and Drug Administration updated its safety communication to remind the public, health care providers, lab personnel and lab test developers that biotin, also known as vitamin B7, often found in dietary supplements, can significantly interfere with certain lab tests and cause incorrect results that may go undetected. The FDA is particularly concerned about biotin interference causing a falsely low result for troponin, a clinically important biomarker to aid in the diagnosis of heart attacks, which may lead to a missed diagnosis and potentially serious health implications.  Biotin is a water-soluble vitamin often found in multi-vitamins, prenatal vitamins and dietary supplements marketed for hair, skin and nail growth. Many dietary supplements contain biotin levels up to 650 times...

Read More